Research by the Association of the British Pharmaceutical Industry has been published which shows that 90% of clinicians and other health professionals surveyed believe that stratified also known as personalised medicine - particularly non-cancer applications - will have a positive impact on the health system in the UK.

Some 61% of  300 polled by Concentra Consulting reported a 'high interest' in emerging uses of non-cancer stratified medicines whilst just 25% reported good access to them in their area currently.

The report also shows that 40% of respondents feel the NHS is currently achieving little or no benefit from non-cancer stratified medicine but that almost a third (32%) believe it gives patients access to treatments they otherwise would not have had.

The report, launched at the ABPI's annual R&D conference being held today (Nov 20), shows that there are currently 41 applications for non-cancer stratified medicines, “of which there is variable knowledge and use across the NHS”. The largest number of applications highlighted in this report were for infection, followed by respiratory and cardiovascular disease.

Clinicians and health professionals unanimously agreed (98%) that there are significant challenges to implementing stratified medicine in the NHS; with 90% claiming that the health system will need to change to support its adoption.